𝕏
Latest

Author

Clara Ashworth

Deals and business correspondent

Clara Ashworth covers biopharma mergers, acquisitions, licensing deals and corporate strategy for PharmaWire, from big-pharma takeovers to early-stage China out-licensing.

Latest from Clara Ashworth

Deals

GSK Bets $10.6 Billion on Cancer with Nuvalent Takeover

GSK (GSK) has agreed to acquire U.S.-listed cancer drug developer Nuvalent (NUVL) for $10.6 billion in its largest deal in more than a decade, marking a decisive shift toward oncology under new chief executive Luke Miels as the British…

Business

AbbVie to Cut 85 Jobs at California Eye Care Unit

AbbVie (ABBV) is eliminating 85 positions at its Irvine, California campus, with the cuts set to take effect July 20, according to a filing under the state's Worker Adjustment and Retraining Notification Act. The layoffs affect the…